Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells

Archives of Medical Research

Volumn 46, Issue 8, 2015, Pages 642-650

  Wang, Denong ^a,b   Liu, Xiaohe ^b   Hsieh, Ben ^c   Bruce, Richard ^c   Somlo, George ^d   Huang, Jiaoti ^e   Sambucetti, Lidia ^b  

^a Tumor Glycomics Laboratory   (United States)

^b SRI INTERNATIONAL   (United States)

^c PALO ALTO RESEARCH CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carbohydrate microarrays; Circulating tumor cells; Metastatic breast cancer; O glycan cryptic antigens; Tumor immunotyping

Indexed keywords

CARBOHYDRATE; EPITOPE; GLYCAN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; TUMOR MARKER;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST METASTASIS; CIRCULATING TUMOR CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH SPEED FIBER OPTIC ARRAY SCANNING TECHNOLOGY; HUMAN; HUMAN CELL; HYBRIDOMA CELL LINE; MICROARRAY ANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR CELL LINE; ADULT; BLOOD; BREAST TUMOR; CLINICAL TRIAL; FEMALE; GLYCOSYLATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; TUMOR EMBOLISM;

ADULT; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLYCOSYLATION; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; POLYSACCHARIDES;

EID: 84957365580     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.11.007     Document Type: Article

References (34)

1. Chatterjee S.K., Zetter B.R. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005, 1:37-50.
2. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989, 52:257-331.
3. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001, 491:369-402.
4. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996, 56:2237-2244.
5. Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005, 4:477-488.
6. Persson J., Backstrom M., Johansson H., et al. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells. Tumour Biol 2009, 30:221-231.
7. Haidopoulos D., Konstadoulakis M.M., Antonakis P.T., et al. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Eur J Surg Oncol 2000, 26:742-746.
8. Renkonen J., Paavonen T., Renkonen R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer 1997, 74:296-300.
9. Nakagoe T., Fukushima K., Itoyanagi N., et al. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 2002, 128:257-264.
10. Abd Hamid U.M., Royle L., Saldova R., et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18:1105-1118.
11. Vassilaros S., Tsibanis A., Tsikkinis A., et al. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013, 5:1177-1182.
12. Apostolopoulos V., Pietersz G.A., Tsibanis A., et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006, 8:R27.
13. Shibata S., Raubitschek A., Leong L., et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 2009, 15:2935-2941.
14. Tomlinson I.P., Whyman A., Barrett J.A., et al. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur J Cancer 1995, 31A:899-902.
15. Jacob K., Sollier C., Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007, 4:741-756.
16. Hayashi N., Yamauchi H. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer 2012, 19:110-117.
17. Somlo G., Lau S.K., Frankel P., et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011, 128:155-163.
18. Das M., Riess J.W., Frankel P., et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012, 77:421-426.
19. Liu X., Hsieh H.B., Campana D., et al. A new method for high speed, sensitive detection of minimal residual disease. Cytometry A 2012, 81:169-175.
20. Wang D., Tang J., Liu S., et al. Blood group precursor cryptic glyco-epitopes as breast cancer cell surface markers for immune recognition and targeting. J Immunol Res 2015, 9. 10.1155/2015/510810.
21. Codington J.F., Sanford B.H., Jeanloz R.W. Glycoprotein coat of the TA3 cell. Isolation and partial characterization of a sialic acid containing glycoprotein fraction. Biochemistry 1972, 11:2559-2564.
22. Li R., Yao J.L., Bourne P.A., et al. Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma. Arch Pathol Lab Med 2004, 128:1412-1417.
23. Liang S., Yao J., Bourne P.A., et al. Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. Am J Clin Pathol 2004, 122:747-751.
24. Yao J.L., Bourne P.A., Yang Q., et al. Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. Arch Pathol Lab Med 2004, 128:785-787.
25. Krivacic R.T., Ladanyi A., Curry D.N., et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004, 101:10501-10504.
26. Hsieh H.B., Marrinucci D., Bethel K., et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21:1893-1899.
27. Maisonrouge McAuliffe F., Kabat E.A. Immunological studies on blood groups. Structures and immunochemical properties of oligosaccharides from two fractions of blood group substance from ovarian cyst fluid differeing in B, I, and i activities and reactivity toward Concanavalin A. Arch Biochem Biophys 1976, 175:90-113.
28. Maisonrouge-McAuliffe F., Kabat E.A. Immunochemical studies on blood groups. Heterogeneity of oligosaccharides liberated by degradation with alkaline borohydride of two human ovarian cyst fractions differing in B, I, and i activities and in reactivity toward concanavalin A. Arch Biochem Biophys 1976, 175:81-89.
29. Maisonrouge-McAuliffe F., Kabat E.A. Immunochemical studies on blood groups. Fractionation, heterogeneity, and chemical and immunochemical properties of a blood group substance with B, I and i activities purified from human ovarian cyst fluid. Arch Biochem Biophys 1976, 175:71-80.
30. b and precursor substances. J Exp Med 1972, 135:1247-1258.
31. Feizi T. Blood group antigens. Ii antigens. Proc R Soc Med 1975, 68:799-802.
32. Wang D., Dafik L., Nolley R., et al. Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer. Drug Dev Res 2013, 74:65-80.
33. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Breast Cancer 2009, 9(suppl 2):S73-S81.
34. Brenton J.D., Carey L.A., Ahmed A.A., et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-7360.